Keratoconjunctivitis: Clinical Trials

13 trials for Keratoconjunctivitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 withdrawn. 13 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 413Completed 10, Withdrawn 3

Follow Keratoconjunctivitis: new trials by email Literature Review of Keratoconjunctivitis trials Research Report on Keratoconjunctivitis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Nasal Guide - Dry Eye, Keratoconjunctivitis Sicca
Phase 4CompletedOyster Point Pharma, Inc.302023-06-142025-05-06
Tolerability Comparison of Flarex to Lotemax SM
Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38% - Ocular Inflammation, Keratoconjunctivitis
Phase 4CompletedHarrow Inc402021-05-012026-09-22
Effect of Cequa™ in Subjects With Dry Eye Disease
CequaTM (Cyclosporine 0.09%) ophthalmic solution - Dry Eye Disease
Phase 4CompletedSun Pharmaceutical Industries Limited1352020-06-292024-02-06
Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease
Lifitegrast - Ocular Discomfort, Ocular Inflammation
Phase 4WithdrawnUniversity of Alabama at Birmingham2019-01-012019-05-17
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
repository corticotropin injection - Keratoconjunctivitis Sicca
Phase 4WithdrawnUniversity of Alabama at Birmingham2018-11-012018-12-14
Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness
Lifitegrast - Contact Lens, Contact Lens Discomfort
Phase 4CompletedEV Clinical Trials212016-12-162018-09-28
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
carboxymethylcellulose 0.5%/glycerin 0.9%, sodium hyaluronate 0.18% - Dry Eye Syndromes, Keratoconjunctivitis Sicca
Phase 4CompletedAllergan802014-05-142019-04-18
A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
Retaine™ - Keratoconjunctivitis Sicca
Phase 4CompletedOcusoft, Inc.422014-05-012014-06-11
Effects of Dry Eye Treatments on the Ocular Surface
Dexamethasone, Artificial tear - Keratoconjunctivitis Sicca, Dry Eye Syndrome
Phase 4CompletedBaylor College of Medicine202013-02-012020-02-05
Hyaluronic Acid Gels for Lower Lid Retraction
Hyaluronic acid, Saline - Ectropion
Phase 4WithdrawnUniversity of California, Los Angeles2013-02-012014-12-03
A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis
Zirgan, genteal gel - Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Phase 4CompletedLifelong Vision Foundation202012-01-012018-02-28
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi) - Dry Eye Syndromes, Keratoconjunctivitis Sicca
Phase 4CompletedAllergan822009-11-012011-09-21
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
Lotemax, Restasis - Dry Eye Disease, Keratoconjunctivitis Sicca
Phase 4CompletedOphthalmic Consultants of Long Island52006-11-012011-07-21

Narrower conditions

Dry Eye Syndromes (11)  ·  Keratoconjunctivitis Sicca (11)  ·  Adenoviridae Infections (1)  ·  Conjunctivitis (1)  ·  Ectropion (1)  ·  Postoperative Complications (1)  ·  Xerophthalmia (1)

Broader conditions

Conjunctival Diseases (13)  ·  Corneal Diseases (13)  ·  Eye Diseases (13)  ·  Keratitis (13)  ·  Conjunctivitis (12)  ·  Lacrimal Apparatus Diseases (12)  ·  DNA Virus Infections (1)  ·  Dry Eye Syndromes (1)  ·  Eyelid Diseases (1)  ·  Infections (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Virus Diseases (1)

Interventions

Carboxymethylcellulose Sodium (2)  ·  Hyaluronic Acid (2)  ·  Lubricant Eye Drops (2)  ·  lifitegrast (2)  ·  Adrenal Cortex Hormones (1)  ·  Cyclosporine (1)  ·  Cyclosporins (1)  ·  Dexamethasone (1)  ·  Fluorometholone (1)  ·  Ganciclovir (1)  ·  Glycerol (1)  ·  Loteprednol Etabonate (1)  ·  Ophthalmic Solutions (1)  ·  Restylane (1)  ·  Sodium Chloride (1)

Sponsors

Allergan (2)  ·  University of Alabama at Birmingham (2)  ·  Baylor College of Medicine (1)  ·  EV Clinical Trials (1)  ·  Harrow Inc (1)  ·  Lifelong Vision Foundation (1)  ·  Ocusoft, Inc. (1)  ·  Ophthalmic Consultants of Long Island (1)  ·  Oyster Point Pharma, Inc. (1)  ·  Sun Pharmaceutical Industries Limited (1)  ·  University of California, Los Angeles (1)

Countries

United States (10)  ·  France (2)  ·  United Kingdom (1)

Top investigators

Daniel B Rootman, MD, MSc (1)  ·  Jai Parekh, MD, MBA (1)  ·  Jason J Nichols, OD, MPH, PhD (1)  ·  Jay S Pepose, MD, PhD (1)  ·  John Sheppard, MD (1)  ·  Joshua Davidson, OD, FAAO (1)  ·  Kelly K Nichols, OD MPH PhD (1)  ·  Kevin L Waltz, OD, MD (1)  ·  Maria Howard (1)  ·  Marian Macsai, MD (1)  ·  Mujtaba A Qazi, MD (1)  ·  Parag A Majmudar, MD (1)  ·  Ruben L BonSiong, MD (1)  ·  Stephen Pflugfelder, MD (1)

Results publications

PMID 25083776